Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, and Chronic Lymphocytic Leukemia Research.
Chronic myeloid leukaemia: Biology and therapy
Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine for Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): AK117-103 Phase 1b Results
A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Effectivness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China
Myelodysplastic syndromes
Changing causes of death in persons with haematological cancers 1975–2016
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
The Role of the HOXA Gene Family in Acute Myeloid Leukemia
High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition